[Ala1,3,11,15]-Endothelin
(Synonyms: [丙氨酸1,3,11,15]-内皮素1,[Ala1,3,11,15] Endothelin-1; human; (Ala?·?·??·??)-Endothelin-1 trifluoroacetate salt) 目录号 : GC17744
一键复制产品信息
[Ala1,3,11,15]-Endothelin是一种经过修饰的Endothelin-1线性类似物，特点在于将原始序列中第1，3，11，15位的氨基酸替换为Alanine。
![[Ala1,3,11,15]-Endothelin Chemical Structure](https://cdn.glpbio.com/thumbs/struct/GC1/GC17744.png "[Ala1,3,11,15]-Endothelin Chemical Structure")
Cas No.:121204-87-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
[Ala1,3,11,15]-Endothelin is a modified linear analogue of endothelin-1, characterized by the substitution of alanine for the native amino acids at positions 1, 3, 11, and 15 of the original sequence[1-2]. [Ala1,3,11,15]-Endothelin acts as a selective endothelin B (ETB) receptor agonist with an IC₅₀ ranging from 0.33nM to 0.61nM and is commonly used in studies related to vasoconstriction and receptor function[3-4].
In vitro, when Chinese hamster ovary (CHO) cells stably expressing human ETB receptors were treated with 100nM [Ala1,3,11,15]-Endothelin for 20 minutes, [Ala1,3,11,15]-Endothelin significantly stimulated cytosolic phospholipase A₂ activity and promoted prostaglandin E₂ secretion[5]. In wounded human umbilical vein endothelial cell (HUVEC) monolayers, treatment with 10–100nM [Ala1,3,11,15]-Endothelin for 18 hours. [Ala1,3,11,15]-Endothelin enhanced wound repair by promoting cell proliferation rather than migration[6].
In vivo, intravenous administration of [Ala1,3,11,15]-Endothelin (0.1–10nmol/kg) induced a biphasic hemodynamic response in anesthetized rats. During the initial phase (1–3 minutes), [Ala1,3,11,15]-Endothelin caused a significant decrease in mean arterial pressure accompanied by vasodilation in the carotid, coeliac, and iliac arterial regions, along with marked vasoconstriction in the mesenteric and renal arteries. In the later phase (15–20 minutes), [Ala1,3,11,15]-Endothelin increased in blood pressure and systemic vasoconstriction[7].
References:
[1] Nakamichi K, Ihara M, Kobayashi M, et al. Different distribution of endothelin receptor subtypes in pulmonary tissues revealed by the novel selective ligands BQ-123 and [Ala1,3,11,15]ET-1. Biochem Biophys Res Commun. 1992 Jan 15;182(1):144-50.
[2] Webber KM, Pennefather JN, Head GA, et al. Endothelin induces dopamine release from rat striatum via endothelin-B receptors. Neuroscience. 1998 Oct;86(4):1173-80.
[3] Saeki T, Ihara M, Fukuroda T, et al. [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity. Biochem Biophys Res Commun. 1991 Aug 30;179(1):286-92.
[4] Wong J, Reddy VM, Hendricks-Munoz K, et al. Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol. 1995 Dec;269(6 Pt 2):H1965-72.
[5] Schramek H, Wang Y, Konieczkowski M, et al. Endothelin-1 stimulates cytosolic phospholipase A2 in Chinese hamster ovary cells stably expressing the human ETA or ETB receptor subtype. Biochem Biophys Res Commun. 1994 Mar 15;199(2):992-7.
[6] Wren AD, Hiley CR, Fan TP. Endothelin-3 mediated proliferation in wounded human umbilical vein endothelial cells. Biochem Biophys Res Commun. 1993 Oct 15;196(1):369-75.
[7] Bigaud M, Pelton JT. Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992 Dec;107(4):912-8.
[Ala1,3,11,15]-Endothelin是一种经过修饰的Endothelin-1线性类似物，特点在于将原始序列中第1，3，11，15位的氨基酸替换为Alanine[1-2]。[Ala1,3,11,15]-Endothelin是内皮素B受体（ETB）的激动剂，对ETB受体的IC50值范围在0.33nM至0.61nM之间，可用于血管收缩及相关受体功能的研究[3-4]。
在体外，[Ala1,3,11,15]-Endothelin（100nM）处理稳定表达人ETB受体的中国仓鼠卵巢细胞（CHO细胞）20分钟，[Ala1,3,11,15]-Endothelin显著刺激胞质磷脂酶A2活性，并促进前列腺素E2的分泌[5]。[Ala1,3,11,15]-Endothelin（10–100nM）处理损伤的人脐静脉内皮细胞（HUVEC）18小时，[Ala1,3,11,15]-Endothelin显著增强细胞单层修复能力，通过促进增殖而非迁移加速伤口愈合[6]。
在体内，[Ala1,3,11,15]-Endothelin（0.1–10nmol/kg）静脉注射诱导了大鼠双相血流动力学反应。[Ala1,3,11,15]-Endothelin在初期（1–3分钟内）引起大鼠平均动脉压显著下降，伴随颈动脉、腹腔和髂动脉区域的血管舒张，同时肠系膜和肾动脉出现明显血管收缩。[Ala1,3,11,15]-Endothelin在后期（15–20分钟）引起大鼠出现血压升高及系统性血管收缩[7]。
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVEC) |
Preparation Method | HUVEC were isolated from umbilical veins and cultured in Medium E199 supplemented with 15% fetal calf serum, 2mM L-glutamine, and antibiotics at 37°C under 5% CO₂. Confluent monolayers were wounded using a Perspex comb and treated with [Ala1,3,11,15]-Endothelin (10–100nM) in medium. |
Reaction Conditions | 10–100nM; 18 hours post-wounding. |
Applications | [Ala1,3,11,15]-Endothelin significantly enhanced wound repair in HUVEC monolayers by promoting cell proliferation, as confirmed by increased cell counts. This effect was concentration-dependent and unaffected by ETA or ETA/ETB receptor antagonists (BQ-123 or PD142893). Actinomycin D abolished the proliferative response, indicating dependence on de novo protein synthesis. The peptide acted directly without involving cyclo-oxygenase pathways or basic fibroblast growth factor (bFGF) signaling. |
| Animal experiment [2]: | |
Animal models | Anesthetized Sprague-Dawley rats |
Preparation Method | Rats were instrumented with ultrasonic Doppler flow probes on carotid, coeliac, mesenteric, renal, and iliac arteries. [Ala1,3,11,15]-Endothelin was administered intravenously as a bolus injection (0.1–10nmol/kg), with hemodynamic parameters monitored for 30 minutes. |
Dosage form | 0.1–10nmol/kg; i.v.; Single injection. |
Applications | [Ala1,3,11,15]-Endothelin induced a biphasic hemodynamic response: an initial marked decrease in mean arterial pressure accompanied by vasodilation in carotid, coeliac, and iliac beds, and concurrent vasoconstriction in mesenteric and renal beds. This was followed by a mild secondary pressor effect with systemic vasoconstriction. Pretreatment with the ETA receptor antagonist BQ-123 (1.6μmol/kg) abolished the secondary vasoconstrictor response but did not affect the early vasodilator component, confirming ETB receptor-mediated vasodilation and partial ETA-dependent vasoconstriction. |
References: | |
| Cas No. | 121204-87-3 | SDF | |
| 别名 | [丙氨酸1,3,11,15]-内皮素1,[Ala1,3,11,15] Endothelin-1; human; (Ala?·?·??·??)-Endothelin-1 trifluoroacetate salt | ||
| Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/ | ||
| 分子式 | C109H163N25O32S | 分子量 | 2367.67 |
| 溶解度 | Soluble to 1 mg/ml in Water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 422.4 μL | 2.1118 mL | 4.2236 mL |
| 5 mM | 84.5 μL | 422.4 μL | 844.7 μL |
| 10 mM | 42.2 μL | 211.2 μL | 422.4 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet